Thermo Fisher's (TMO) CytoScan HD Accel array can save labs weeks or even months by accelerating the time it takes to get findings from cytogenetic research.

The diagnostic yield of CytoScan Dx Assay in 960 patients was assessed with the Riggs criteria of actionability to evaluate predicted clinical utility.

Introducing the new CytoScan HD Accel microarray that significantly improves the power and speed of genome-wide copy number analysis using industry-leading Chromosomal Microarray (CMA). The highly ...

Hamilton Robotics has announced that the soon-to-launch CytoScan Automated Target Preparation Solution from Affymetrix, Inc. is built on the customizable Microlab® NIMBUS 96 workstation from Hamilton ...

The Affymetrix CytoScan HD Array interrogates the entire genome using more than 2.6 million markers for copy-number analysis and approximately 750,000 SNPs. The platform offers excellent ...

Affymetrix gained the FDA's OK for its CytoScan Dx Assay, a first-of-its-kind blood test that can identify possible genetic causes behind a child's developmental delay or intellectual disability.

Thermo Fisher Scientific Inc., the world leader in serving science, announced today that the Applied Biosystems™ CytoScan™ Dx Assay and Applied Biosystems™ C ...

The CytoScan Dx Assay (Affymetrix) is a first-of-a-kind postnatal blood test to help diagnose developmental delays and intellectual disabilities in children, the FDA says.

A unique blood test that can help diagnose learning disabilities in babies by analyzing their genetic code has been approved by the Food and Drug Administration.

Thermo Fisher Scientific, Inc. TMO recently launched the Applied Biosystems CytoScan HD Accel array — a new chromosomal microarray intended to enhance cytogenetic research lab productivity ...